balance, sleepiness, and confusion, and without the potential for addiction. They found one-NaV1.7-which is encoded by the gene SCN9A [2] .
The Waxman lab launched a worldwide search for families that have inherited neuropathic pain, and expected that individuals in these groups might carry genetic markers that would help them to learn a lot about more neuropathic disorders. They found mutations of SCN9A, the gene for NaV1.7, in families with Inherited Erythromelalgia (IEM), and these mutations resulted in overactive NaV1.7 channels, causing extreme pain for these patients. They also found families with loss-of-function mutations, so these individuals feel no pain, placing them at risk of experiencing fractures or burns without noticing. His research group utilizes both genomics and biophysical modeling on these rare disorders in their attempts to transform pain treatment to a rational, genomic data guided approach.
Dr. Waxman, could you tell me a bit about your background and how you got to where you are today?
I've always been interested in science, and became interested in neuroscience early on. When I decided to go to an MD/PhD program, a real driver for me was doing mechanistic science on neurological disorders thought to be incurable in order to understand them and hopefully develop treatments to ultimately cure them.
So, I guess what I'm best known for is working out the molecular basis for remission in multiple sclerosis (MS). We're taught and we continue to teach that after injury, the brain and spinal cord don't display much functional recovery, but we often see functional recovery in MS. We wanted to understand whether or not we can induce functional recovery in disorders of the CNS and MS seemed to be a good human model. This was an early focus of mine. It turned out to be a story of ion channel function/dysfunction and expression/misexpression in myelinated and demyelinated axons, and that theme has been a continuing cord throughout my research. Then, some years ago, my research group became interested in neuropathic pain, which is pain associated with dysfunction or disease of the nervous system which is an immense unmet medical need. It turns out that sodium channels are very important players in that disease process.
Is there anything specific in your background that has made you interested in the study of pain and the nervous system?
There was no personal exposure to pain early on, but later in my career, I watched my father in his last years. He had diabetic neuropathic pain, and as a clinician, I saw him experience excruciating discomfort. There were attempts to treat him with opiates, but they just caused confusion; the pain was still there.
I've always been interested in why some patients have extreme pain and other patients who have an apparently similar diagnosis in a structural sense will come to clinic feeling like their hands are numb, but without substantial pain.
Another personal aspect that developed later on that I did not imagine at the front end was how close of a relationship would develop between me as an investigator and those with the diseases that I study, particularly IEM. It's become clear that the people we work with, who have rare diseases, have given us an immense gift by giving us their DNA and the stories of their medical histories, and in turn, we have been able to at least make some progress on their disease, which is a very gratifying aspect.
How do you think your training as a physician scientist has aided you in your experience?
For me, having both an MD and a PhD degree, the MD degree is a tablet of human biology, which has alerted me to the human implications of the biology that I love to do. I am motivated by basic biological questions, namely how do neurons build excitable membranes with the right ensemble of channels and receptors so as to achieve the right form of excitability for that type of neuron? My medical training has alerted me to the fact that there are diseases in humans that provide a form of comparative physiology that can teach us a lot. And that what we learn may inform new approaches to therapy. Of course there are basic scientists who know as much about specific diseases than most MDs-one does not need to go to medical school, but gaining knowledge on human diseases adds breadth and depth to a research program.
What is your opinion on current pain treatment practices?
My opinion is very simple-it is grossly inadequate. Many of the existing pain medications are either ineffective or are only partially effective, and they have side effect profiles that limit their usage. We have to do better. Right now, we are in the middle of the molecular revolution, with all the necessary tools, but we have to put those tools to the proper use.
In terms of pain manifestation, do clinicians have to take different approaches to treat different types of pain?
There are a couple of issues. Right now, we classify pain based on clinical criteria that in part depends on patient history, and how precise or imprecise we are often depends on diagnostic terminology. Currently, the diagnostic categories are driven by clinical criteria, not molecular criteria. I feel that we would be in a better position if we could categorize pain based on the molecular pathogenesis or etiology. Different types of pain may require different types of treatment based on the molecular target that must be engaged. And, we not only have different types of pain with different characteristics, but we also have a group of patients that do not feel pain. In this lab, we have been working on NaV1.7 which is a master regulator of pain. Gain-of-function mutations lead to severe pain, while patients with loss-of-function mutations don't feel pain and accumulate painless injuries that result in severe disability. In this lab, we are primarily focused on gain-of-function, but there is no question that loss-of-function also presents a major clinical challenge, and gene therapy may help these patients as well.
Do you think there's a barrier to treatment and seeking out medical help in patients that have pain but no obvious outward sign of it (such as rheumatoid arthritis, systemic lupus erythematosus, etc.)?
I think there are a couple barriers. One is that we cannot see pain, and another is that we do not yet do a good job of objectively measuring pain. In experimental studies on humans, you may ask a patient to rate their pain from zero, or no pain, to ten, the worst pain they can imagine, and that is a very fuzzy, low-resolution scale. It can also be influenced by distractibility and sleep status. Placebo response in clinical trials is large. Existing animal models are not highly predictive of human therapeutic response, so we have a lot of barriers there. In addition, pain has multiple axes.
For example, in one individual that I saw in the clinic, they were able to describe five different kinds of pain, and they have taken multiple kinds of medications, and this individual said that one of these medications actually only helps one of those five kinds of pain. But most clinicians don't ask patients to describe their pain. I think we fail to explore the multiple axes of pain for many patients in the clinic, so we have a lot of work to do in this respect with understanding those and characterizing them more clearly.
In your research, how do you make use of human models of disease?
We are developing a number of disease-in-a-dish models. We are able to construct human mutant channels, transfect them into rodent sensory neurons growing in culture, and then recreate the disease there, but we are also taking blood from individuals with genetically-associated pain syndromes, then differentiating that into induced pluripotent stem cells, and then differentiate those into sensory-like neurons, which reproduce the hyper-excitability and abnormal spontaneous firing that occurs in patients with gain-of-function mutations. So, with that, we have a disease-in-a-dish model derived from induced pluripotent stem-cells that preserves the entire genome from the particular patient of study.
With treatment, in terms of overactive channels, does treatment intend to return to a normal state or to stop them altogether?
Most of the large and small molecules coming out of the pharmaceutical industry aim to block activity of the channels. That is achieved by a variety of types of molecules that are in various stages of development, but our in-house pharmacogenomics studies at Yale have showed that one existing drug, which acts as a sodium channel blocker, has a normalizing effect in certain mutant channels. We are still trying to understand the effect itself, and our experiments suggest that the drug has two mechanisms of action; one mechanism of action is to partially normalize the activity of mutant channels and thus some mutations. We think it only acts on some mutants such that nature is trying to give us a clue of the structural intermolecular substrates for this second method of action, such that we can develop a model of it. I'm pretty confident that, ultimately, a "precision medicine" approach to pain, guided by genomics and structural modeling, can be developed. We've already been successful with this approach with a small number of gene variants.
As you continue on your clinical research path, what gaps still exist in our knowledge that you are excited about pursuing?
We need to understand, with an increasingly fine resolution, the structural biology of molecules involved in pain. Even beyond the molecules I am interested in, there is much more to what I call the electrogenisome, which is the hundreds of molecules that shape neuronal excitability. There is a lot to learn about how nerve cells develop electrogenic membranes, and about how these work.
There are mysteries about IEM. For example, the pain is most intense in the areas innervated by the longest nerve fibers, specifically the hands and feet-why is there this length dependence? Patients with gain-of-function mutations in these sodium channels carry these mutations throughout life, but often have adult-onset of their symptoms-why do they not feel pain until they are adults? Why is this pain process time-and length-dependent?
In my view, precision medicine for pain is an important goal, and I like to think our work is a small step forward showing in a very palpable, clear way that it is achievable. In our case, we have moved one gene variant at a time. So the work we have done only applies to a small number of patients. Moving ahead with precision medicine, it would be exciting to use big data analysis to do it in a broad or big way. We have target molecules-we can explore their gene variants at the atomic level using atomic modeling, biophysics of channel function, putting variant channels into pain-signaling neurons and explore their influence on cell function and the firing of the pain signaling pathway, all in a patient-specific way.
For at least a small number of these variants, we can project on the basis of structural biology and biophysics and pharmacology, and we can predict the efficacy of drugs, both on cells carrying that channel in vitro, and in human subjects carrying that channel. It's taken a long time to do that and we've only been able to do it for a small number of gene variants, and this has taught me how persistent one must be to translate from the laboratory to the human domain, but it can be done, so I am encouraged.
Those are just a few examples of the kinds of questions that I am thinking about. One of the things I love about research is that new unanswered questions appear every day. It is almost like I am receiving a unique new puzzle box each day; I can't always answer the question immediately, but they're very exciting to think about.
Is there anything else you think is important for readers to know?
There is a sort of subtext-there is often pessimism in the neuroscience community about the slow pace of translation and about whether translation from the laboratory to the clinic can occur. Up to this point, common treatments for stroke exist, but they work on the vasculature. Diseases like MS are eminently treatable, but the treatments focus on the immune system. There has been less progress in terms of focusing on neuroscience and neurobiological mechanisms. Even though it has not happened yet, I am positive that it can and will.
In our research group, we have been able to carry out studies from genes to gene product to nerve cells to humans to studies on novel therapies with encouraging results. We have a lot more to do, but I hope that researchers can remain positive about the path ahead.
For scientists who are interested in translational research, in order to move from the laboratory all the way to humans, you need to be strategic and persistent, and you need to buckle up for a long and sometimes bumpy ride. If you get into that car, have your goal in mind, get the best collaborators you can, and stay with it. I have confidence that the future will be bright.
